97 related articles for article (PubMed ID: 3071992)
41. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
42. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein PS; DeVita VT; Hubbard S; Chabner BA; Canellos GP; Berard C; Young RC
Ann Intern Med; 1976 Oct; 85(4):417-22. PubMed ID: 61732
[TBL] [Abstract][Full Text] [Related]
43. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
[TBL] [Abstract][Full Text] [Related]
44. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
[TBL] [Abstract][Full Text] [Related]
45. Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
Lee HS; Park LC; Lee EM; Shin SH; Ye BJ; Oh SY; Song MK; Lee SM; Lee WS; Kang BW; Chang MH; Cho SG; Yahng SA; Yoon SS; Kwon JH; Kim YS
Am J Clin Oncol; 2014 Apr; 37(2):182-7. PubMed ID: 23211226
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.
Fisher RI; DeVita VT; Johnson BL; Simon R; Young RC
Am J Med; 1977 Aug; 63(2):177-82. PubMed ID: 70170
[TBL] [Abstract][Full Text] [Related]
47. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.
Hong J; Park S; Park J; Kim HS; Kim KH; Ahn JY; Rim MY; Jung M; Sym SJ; Cho EK; Shin DB; Lee JH
Leuk Lymphoma; 2011 Oct; 52(10):1904-12. PubMed ID: 21718130
[TBL] [Abstract][Full Text] [Related]
49. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
50. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
51. [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].
Zhang HY; Guan ZZ; Wang B; Huang HQ; Xia ZJ; Lin TY
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):381-4. PubMed ID: 18953841
[TBL] [Abstract][Full Text] [Related]
52. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
53. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
54. Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.
Basit A; Siddiqui N; Muzaffar N; Awan UK; Bashir H; Khan SA; Hameed A
J Pak Med Assoc; 2016 Apr; 66(4):380-6. PubMed ID: 27122261
[TBL] [Abstract][Full Text] [Related]
55. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
[TBL] [Abstract][Full Text] [Related]
57. [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
Su ZY; Zhang DS; Zhu MQ; Shi YX; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):919-22. PubMed ID: 17697560
[TBL] [Abstract][Full Text] [Related]
58. Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
Johnson GJ; Costello WG; Oken MM; Sponzo RW; Barnes JM; Ezdinli EZ; Bennett JM; Silverstein MN; Glick JH; Berard CW
Cancer; 1983 Oct; 52(7):1133-41. PubMed ID: 6192894
[TBL] [Abstract][Full Text] [Related]
59. 18F-Fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma.
Odawara J; Asada N; Aoki T; Yamakura M; Takeuchi M; Ohuchi T; Matsue K
Br J Haematol; 2007 Mar; 136(5):684. PubMed ID: 17129231
[No Abstract] [Full Text] [Related]
60. Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy.
Song MK; Chung JS; Shin DY; Lim SN; Lee GW; Choi JC; Park WY; Oh SY
Ann Hematol; 2017 Jan; 96(1):17-23. PubMed ID: 27677489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
